An Open-Label Study to Assess the Efficacy and Potential for Adrenal Suppression Following Maximal Use Treatment With TA-102 Topical Formulations in Subjects With Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs TA-102 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Taro Pharmaceuticals USA
- 09 Sep 2019 Planned End Date changed from 15 Mar 2019 to 15 Dec 2019.
- 09 Sep 2019 Planned primary completion date changed from 15 Jan 2019 to 15 Oct 2019.
- 09 Sep 2019 Status changed from recruiting to active, no longer recruiting.